截至发稿，邹建累计任职时间4年292天，现任基金资产总规模12.12亿元，任职期间最佳基金回报 14.09%， 任职期间最差基金回报-21.29%。 从基金十大重仓股角度 数据显示，大成基金旗下1只基金重仓三鑫医疗。大成创业板两年定开混合A（160926）三季度增持15 万股，持有股数273.26万股，占基金净值比例为3.23%，位居第八大重仓股。根据测算，今日浮盈赚取 约136.63万元。 数据显示，大成基金旗下1只基金位居三鑫医疗十大流通股东。大成创业板两年定开混合A（160926） 三季度新进十大流通股东，持有股数273.26万股，占流通股的比例为0.76%。根据测算，今日浮盈赚取 约136.63万元。 大成创业板两年定开混合A（160926）成立日期2020年7月16日，最新规模5.82亿。今年以来收益 26.07%，同类排名3476/8147；近一年收益19.24%，同类排名3487/8056；成立以来收益12.73%。 大成创业板两年定开混合A（160926）基金经理为邹建。 11月12日，三鑫医疗涨5.07%，截至发稿，报10.36元/股，成交1.22亿元，换手率3.39%，总市值54.09亿 ...

11月12日，三鑫医疗涨5.07%，截至发稿，报10.36元/股，成交1.22亿元，换手率3.39%，总市值54.09亿 元。 资料显示，江西三鑫医疗科技股份有限公司位于江西省南昌县小蓝经济开发区富山大道999号，成立日 期1997年3月7日，上市日期2015年5月15日，公司主营业务涉及医疗器械研发、制造、销售和服务。主 营业务收入构成为：血液净化类82.23%，给药器具类10.83%，心胸外科类4.60%，其他类2.34%。 截至发稿，周冲累计任职时间3年101天，现任基金资产总规模1161.54万元，任职期间最佳基金回报 4.91%， 任职期间最差基金回报-10.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，汇安基金旗下1只基金重仓三鑫医疗。汇安资产轮动混合A（005360）三季度减持3.63万股， 持有股数11.71万股，占基金净值比例为9.2%，位居第一大重仓股。根据测算，今日浮盈赚取约5.86万 ...

Core Viewpoint - Ningbo Tianyi Medical achieved significant growth in revenue and net profit in the first three quarters of 2025, driven by strong sales in blood purification and ward care products [1] Company Performance - The company reported a revenue of 387 million yuan, representing a year-on-year increase of 24.14% [1] - The net profit attributable to shareholders reached 20.09 million yuan, marking a year-on-year growth of 216.81% [1] Industry Environment - The domestic blood purification market is entering a growth phase, with increasing numbers of kidney disease patients and rising reimbursement rates for dialysis costs [2] - The market size of China's blood dialysis industry is projected to grow from 42 billion yuan in 2020 to 73.5 billion yuan in 2024, with a compound annual growth rate of 14.8% [2] Product Competitiveness - The company focuses on technological innovation as a core development driver, establishing a medical extracorporeal circulation blood path engineering center to strengthen its technical advantages in blood purification consumables [2] - Tianyi Medical has developed over 200 specifications of extracorporeal circulation blood path products to meet diverse clinical needs, enhancing market recognition [2] Strategic Initiatives - The company has strategically acquired businesses to fill gaps in its operations and expand its market presence, including a 60 million yuan investment in Ningbo Tianhuiyi and the acquisition of CRRT business from Nikkiso Co., Ltd [3] - The acquisition of BELLCO S.R.L.'s CRRT filter business assets was completed in September, allowing the company to establish a complete CRRT product line and a self-sustaining operational ecosystem for CRRT products [3]

Group 1 - The stock price of Sanxin Medical closed at 9.78 yuan on August 27, down 0.32 yuan, a decrease of 3.17% from the previous trading day [1] - The opening price was 10.08 yuan, with a high of 10.17 yuan and a low of 9.68 yuan, and the trading volume reached 212,400 hands, with a transaction amount of 211 million yuan [1] - Sanxin Medical's main business includes the research, production, and sales of medical devices, covering areas such as blood purification, injection, and indwelling catheter products, primarily used for hemodialysis treatment in patients with acute and chronic renal failure [1] Group 2 - The stock repurchase plan of Sanxin Medical has been approved by the shareholders' meeting, with a proposed repurchase amount not exceeding 1.0024 million yuan, indicating the company's confidence in its own development [1] - On August 27, the net outflow of main funds for Sanxin Medical was 37.7674 million yuan, accounting for 1.08% of the circulating market value, with a cumulative net outflow of 96.8012 million yuan over the past five trading days, representing 2.77% of the circulating market value [1]

Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. reported a revenue of 761 million yuan in the first half of 2023, marking a year-on-year increase of 10.83%, with a net profit of 115 million yuan, up 8.35% year-on-year [2] Group 1: Financial Performance - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was 103 million yuan, reflecting a year-on-year growth of 9.26% [2] - Revenue from blood purification products reached 626 million yuan, representing a year-on-year increase of 19.73%, accounting for 82.23% of total revenue [3] - The gross margin for blood purification products was 34.30%, showing an increase compared to the previous year [4] Group 2: Market Expansion - The company achieved significant breakthroughs in overseas markets, with international sales revenue reaching 187 million yuan, a year-on-year increase of 67.30% [6] - Blood purification product exports contributed 165 million yuan to overseas sales, accounting for 88% of total export revenue, with an increase of 83.84% year-on-year [6] - The company is focusing on emerging markets along the "Belt and Road" initiative, which have large and growing populations, providing substantial market opportunities [6] Group 3: Industry Trends - The global end-stage renal disease (ESRD) patient population is projected to grow from 11.14 million in 2023 to 13.29 million by 2027, with a compound annual growth rate of 4.51% [3] - The demand for blood purification products is expected to remain strong due to the increasing number of ESRD patients and the essential nature of these products in treatment [4][3]

Core Viewpoint - Sanxin Medical is accelerating its expansion in the blood dialysis sector by issuing convertible bonds to raise up to 530 million yuan for various blood dialysis-related projects and to supplement working capital [1][2]. Group 1: Fundraising and Investment Projects - The company plans to raise a total of no more than 530 million yuan, with the net proceeds allocated entirely to three expansion projects and working capital [2]. - The largest portion of the funds, 210 million yuan (39.62% of total fundraising), will be used for the expansion of the annual production capacity of 10 million blood dialysis membranes and 10 million blood dialysis devices [2]. - Another project, focusing on the construction of a new production line for 30 million blood dialysis tubing, will receive 166 million yuan [3]. - A project for the renovation of the irradiation sterilization production line will utilize 24 million yuan, enhancing product sterilization quality [3]. - Additionally, 130 million yuan will be allocated to supplement working capital, optimizing the company's financial structure and liquidity [3]. Group 2: Business Performance and Growth - Sanxin Medical's revenue from blood purification products has increased significantly, with the proportion of total revenue rising from 73.02% in 2023 to 82.28% in the first half of 2025 [1][5]. - The company reported a revenue of 761 million yuan in the first half of 2025, a year-on-year increase of 10.83%, and a net profit of 115 million yuan, up 8.35% [1][5]. - The total assets of Sanxin Medical reached 2.246 billion yuan in the first half of 2025, marking a 10.1% year-on-year growth and setting a historical high [1][6]. Group 3: Market Expansion and R&D - The company has shifted its focus from injection and infusion products to blood dialysis, achieving a compound annual growth rate of 19.07% in total revenue from 312 million yuan in 2015 to 1.5 billion yuan in 2024 [4][5]. - Sanxin Medical is actively expanding its market presence in Southeast Asia, the Middle East, Latin America, and Africa, with successful registrations in countries like Indonesia, Peru, and Mexico [5]. - The company has invested significantly in R&D, with a total of 256 million yuan spent from 2022 to the first half of 2025, resulting in 203 authorized patents and 121 pending patents [6].

Core Viewpoint - Sanxin Medical (300453) demonstrated steady growth in its 2025 mid-year report, with significant increases in revenue and net profit, particularly in the overseas market [2][12]. Business Overview - Total revenue reached 761 million yuan, a year-on-year increase of 10.83%, while net profit attributable to shareholders was 115 million yuan, up 8.35% [2]. - In Q2 alone, revenue was 400 million yuan, reflecting a 12.65% year-on-year growth, and net profit was 61.39 million yuan, increasing by 16.65% [2]. Main Business Analysis - **Blood Purification Products**: This core business accounted for over 80% of total revenue, generating 626 million yuan with a gross margin of 34.30% [3]. - **Drug Delivery Devices**: Revenue from this segment was 82.41 million yuan, making up 10.83% of total revenue, with a gross margin of 27.15% [4]. - **Cardiothoracic Products**: This category generated 34.98 million yuan, representing 4.60% of total revenue, with a high gross margin of 64.09% [5]. Financial Metrics Analysis - **Profitability**: The company maintained a gross margin of 34.97% and a net margin of 16.72%, despite slight decreases of 0.34 and 0.54 percentage points respectively [6]. - **Cost Control**: Total selling, administrative, and financial expenses were 94.80 million yuan, accounting for 12.46% of revenue, a decrease of 3.58 percentage points year-on-year [7]. - **Cash Flow**: Operating cash flow per share was 0.36 yuan, up 38.20%, with cash and cash equivalents increasing by 70.74% to 216 million yuan [8]. Overseas Market Performance - Revenue from overseas markets reached 187 million yuan, a significant year-on-year increase of 67.30%, accounting for 24.58% of total revenue [9]. Development Prospects - The medical device industry is rapidly growing, with projections indicating a market size of 1,813.4 billion yuan by 2035 in China. As a leading player, the company is well-positioned to benefit from this growth, especially in the blood purification sector due to the increasing number of end-stage renal disease (ESRD) patients [11].

Core Viewpoint - The company plans to issue convertible bonds to unspecified investors, which may dilute immediate returns for existing shareholders, and has outlined measures to mitigate this dilution [1][4][5]. Financial Impact Analysis - The issuance of convertible bonds is expected to lead to a dilution of earnings per share (EPS) in the short term, with projections showing a decrease in diluted EPS from 0.44 to 0.39 under certain profit growth scenarios [2][3]. - The company has simulated financial impacts under three scenarios of net profit growth: no growth, 10% growth, and 20% growth, with corresponding EPS adjustments [3]. Necessity and Reasonableness of the Issuance - The funds raised will be used for projects that enhance the company's core competitiveness and sustainable development, including the expansion of production capacity for blood purification products [5][6]. - Specific projects include the expansion of blood dialysis membrane production and the establishment of a new production line for blood purification equipment [5][6]. Relationship with Existing Business - The projects funded by the issuance are closely related to the company's core business of blood purification, which is currently operating at near full capacity [5][6]. - The company aims to alleviate operational funding pressures and support future business development through these investments [5][6]. Measures to Mitigate Dilution - The company plans to enhance its governance structure and internal management to improve operational efficiency and protect shareholder interests [10][11]. - A commitment to improve the efficiency of fund usage and ensure compliance with regulations regarding the management of raised funds has been established [11][12]. Commitment from Major Stakeholders - The controlling shareholders and management have made commitments to ensure the effectiveness of measures to mitigate the dilution of immediate returns [12][13]. - These commitments include not interfering with company operations and ensuring that the interests of shareholders, especially minority investors, are protected [12][13].

Core Viewpoint - Sanxin Medical's stock price showed a fluctuating upward trend on August 4, closing at 9.03 yuan, an increase of 0.56% from the previous trading day [1] Company Overview - The company specializes in the research, production, and sales of medical devices, covering various fields such as blood purification, injection, and indwelling catheters [1] - As a significant player in the medical device industry in Jiangxi province, Sanxin Medical holds a certain influence in its niche market [1] Market Activity - On the trading day, the stock experienced a rapid rebound, with a rise of over 2% within five minutes at 9:40 AM, and a transaction amount of 26.77 million yuan [1] - Despite a net outflow of 4.64 million yuan from main funds on that day, the overall trend over the past five trading days showed a net inflow of 7.51 million yuan [1] - The stock recorded a trading amplitude of 3.23%, with a total trading volume of 136,600 hands and a total transaction amount of 122 million yuan [1]

Group 1 - The core business of the company is the research, manufacturing, sales, and service of medical devices, with main products including blood purification, drug delivery devices, and thoracic surgery products [2] - As of the end of 2024, the company has obtained 203 authorized patents, 121 accepted patents, and holds 102 medical device product registration certificates, demonstrating a strong focus on technological innovation and R&D [2] - The company has received various governmental support for its projects, including recognition as a "National Intellectual Property Advantage Enterprise" and awards for its key technologies in blood dialysis membrane production [2] Group 2 - The company's latest financial performance for Q1 2025 shows revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, with a slight increase of 0.20% year-on-year [2] - The company's current rolling P/E ratio is 19.93, which is significantly lower than the industry average of 55.41 and the industry median of 37.94 [1][3] - The total market capitalization of the company is 4.534 billion yuan, ranking it 41st in the medical device industry [1][3]